Carmignac Gestion Clearside Biomedical, Inc. Transaction History

Carmignac Gestion

$5.71 Billion
Q2 2024

A detailed history of Carmignac Gestion transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Carmignac Gestion holds 2,132,744 shares of CLSD stock, worth $2.18 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

2,132,744

Previous 2,132,744 -0.0%

Holding current value

$2.18 Million

Previous $3.26 Million 15.05%

% of portfolio

0.05%

Previous 0.05%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.82 - $1.27 $219,432 - $339,852	-267,600 Reduced 11.15%	2,132,744 $1.86 Million
Q3 2022 Nov 10, 2022	BUY	$1.08 - $1.83 $10,800 - $18,300	10,000 Added 0.42%	2,400,344 $2.71 Million
Q2 2022 Aug 12, 2022	SELL	$1.3 - $2.49 $123,900 - $237,316	-95,308 Reduced 3.83%	2,390,344 $3.51 Million
Q4 2021 Feb 11, 2022	BUY	$2.72 - $5.72 $27,200 - $57,200	10,000 Added 0.4%	2,485,652 $6.84 Million
Q3 2021 Nov 12, 2021	SELL	$4.83 - $7.2 $4.56 Million - $6.8 Million	-944,225 Reduced 27.61%	2,475,652 $14.9 Million
Q2 2021 Aug 13, 2021	SELL	$2.32 - $5.38 $280,914 - $651,431	-121,084 Reduced 3.42%	3,419,877 $16.7 Million
Q4 2020 Feb 12, 2021	BUY	$1.32 - $2.74 $1.45 Million - $3.01 Million	1,100,000 Added 45.06%	3,540,961 $9.7 Million
Q3 2020 Nov 13, 2020	BUY	$1.45 - $2.0 $729,861 - $1.01 Million	503,353 Added 25.98%	2,440,961 $3.76 Million
Q2 2020 Aug 13, 2020	SELL	$1.55 - $2.41 $66,495 - $103,389	-42,900 Reduced 2.17%	1,937,608 $3.64 Million
Q1 2020 May 14, 2020	BUY	$1.32 - $3.77 $2.61 Million - $7.47 Million	1,980,508 New	1,980,508 $3.37 Million

Others Institutions Holding CLSD

# of Institutions

Shares Held

13.4M

Call Options Held

17.6K

Put Options Held

100

View Full List

About Clearside Biomedical, Inc.

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $61.4M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

More about CLSD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Carmignac Gestion, based on Form 13F filings with the SEC.

News

Stay updated on Carmignac Gestion with notifications on news.

Account

Carmignac Gestion Clearside Biomedical, Inc. Transaction History